All Releases
 |
EDAP Reports 23% Increase in First Quarter 2013 Revenues
May 16, 2013
|
25.1 KB |
|
| |
First quarter 2013 revenue rose 23% to EUR 5.9 million (USD 7.8 million)
Continuing US investments in both FDA regulatory process and US operations
Great momentum and success achieved at two of the world major urology congresses for EDAP's advanced technologies
Publication of two independent studies both reporting 10 y...
|
|
EDAP's Ablatherm-HIFU Receives Two Best Poster Awards at 2013 American Urological Association Annual Meeting
May 14, 2013
|
11.3 KB |
|
| |
Four Scientific Sessions Highlighted HIFU for Treatment of Prostate Cancer
HIFU Featured in Plenary Lecture and Two Moderated Posters at Engineering and Urology Society Meeting
Significant Interest in both HIFU and ESWL Technologies at EDAP Booth
LYON, France, May 14, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the...
|
|
EDAP Schedules Webcast and Conference Call for First Quarter 2013 Results
May 13, 2013
|
10.6 KB |
|
| |
LYON, France, May 13, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its first quarter 2013 results announcement, which will take place on Thursday, May 16, 2013, before the opening of the market.
EDAP will hold a conference call on Thursday, May 16, 2013 ...
|
|
EDAP Outlines Significant Participation at 2013 American Urological Association Annual Meeting
May 1, 2013
|
12.6 KB |
|
| |
Four scientific sessions highlighting HIFU outcomes for treatment of prostate cancer
One AUA accepted poster presentation highlighting Sonolith lithotripter and its exclusive ultrasound Visio Track® localization system
EDAP attending the FDA Public Workshop on prostate cancer clinical trial design issues
LYON, F...
|
|
EDAP Announces 23% First Quarter 2013 Revenue Growth
Apr 11, 2013
|
10.4 KB |
|
| |
First quarter total revenue of approximately EUR 5.9 million (USD 7.8 million), up 23% year-over-year
Ten lithotripsy devices sold in first quarter 2013
Received FDA acceptance for PMA filing on March 26, 2013, for Ablatherm®-HIFU for treatment of low risk, localized prostate cancer
LYON, France, April 11, 2013 ...
|
|
EDAP Reports Fourth Quarter 2012 and Full Year Results
Apr 2, 2013
|
28.7 KB |
|
| |
Highlights
Record fourth quarter 2012 revenue of EUR 9.5 million (USD 12.3 million), up 25.3% year-over-year
Record full year revenue of EUR 26.1 million (USD 33.6 million), up 16.9% year-over-year
Record lithotripsy sales in 2012
PMA for Ablatherm®-HIFU for treatment of low risk, localized pro...
|
|
EDAP Receives U.S. FDA Filing Acceptance of Pre-Market Approval Application
Mar 28, 2013
|
10.2 KB |
|
| |
LYON, France, March 28, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that the U.S. Food and Drug Administration has provided a positive Filing Review Notification on the Company's Pre-Market Approval (PMA) application for its Ablatherm Integrated Imaging HIFU (High Intensity Focuse...
|
|
EDAP Introduces Focal.One(R): A New Robotic HIFU Device for Focal Therapy of Prostate Cancer
Mar 14, 2013
|
12.0 KB |
|
| |
LYON, France, March 14, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the launch of Focal.One®, its new and innovative robotic HIFU device fully dedicated to focal therapy of prostate cancer. Focal.One® will be showcased for the first time at the European Association of Ur...
|
|
EDAP Schedules Webcast and Conference Call for Fourth Quarter and Full Year 2012 Results
Mar 12, 2013
|
10.7 KB |
|
| |
LYON, France, March 12, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its fourth quarter and full year 2012 results announcement, which will take place on Tuesday, April 2, 2013, before the opening of the market.
EDAP will hold a conference call on Tuesda...
|
|
EDAP Receives U.S. FDA Administrative Acceptance Review Notification for Ablatherm(R)-HIFU Pre-Market Approval Application
Mar 7, 2013
|
11.3 KB |
|
| |
LYON, France, March 7, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that the U.S. Food and Drug Administration (FDA) has provided a positive administrative acceptance review notification for the Company's Pre-Market Approval (PMA) application for its Ablatherm Integrated Imaging HI...
|
|
EDAP's Ablatherm-HIFU Offers Reliable Therapy for Localized Prostate Cancer
Feb 22, 2013
|
12.9 KB |
|
| |
LYON, France, Feb. 22, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today new long term data demonstrating high rates of both cancer-specific survival, and freedom from salvage therapy for patients treated with high-intensity focused ultrasound (HIFU) therapy. The study was performed by ...
|
|
EDAP's Ablatherm-HIFU Demonstrates Long-Term Efficacy and Safety Over Fourteen-Year Period
Feb 8, 2013
|
12.2 KB |
|
| |
LYON, France, Feb. 8, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today new data demonstrating the safety and long-term efficacy of Ablatherm-HIFU, an ultrasound guided HIFU device for the treatment of localized prostate cancer. The data was electronically published in January 2013 by t...
|
|
EDAP Submits U.S. FDA Pre-Market Approval Application for Ablatherm(R)-HIFU for Treatment of Low Risk, Localized Prostate Cancer
Feb 1, 2013
|
12.0 KB |
|
| |
LYON, France, Feb. 1, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the submission of its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) on January 31, 2013 for the Company's Ablatherm-HIFU (High Intensity Focused Ultrasound) for treatment of lo...
|
|
EDAP Reports 25% Year-Over-Year Revenue Growth for Fourth Quarter 2012
Jan 22, 2013
|
11.2 KB |
|
| |
Record full year revenue of approximately EUR 26.0 million (USD 33.5 million), up 16.5% year-over-year
Record fourth quarter total revenue of approximately EUR 9.4 million (USD 12.2 million), up 25% year-over-year
Record lithotripsy sales with 21 devices sold in fourth quarter and 52 devices sold during full year
Cash positi...
|
|
EDAP Reports Third Quarter 2012 Results
Nov 21, 2012
|
30.3 KB |
|
| |
Recent Highlights
Recorded robust 13% sales growth over the nine-month period
Strong lithotripsy sales in third quarter and replenished fourth quarter device backlog in lithotripsy and Ablatherm-HIFU
Generated positive cash flow during third quarter 2012
Held productive pre-PMA meeting with U.S. FDA for A...
|
|
EDAP Schedules Webcast and Conference Call for Third Quarter 2012 Results
Nov 7, 2012
|
10.7 KB |
|
| |
LYON, France, Nov. 7, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its third quarter 2012 results announcement, which will take place on Wednesday, November 21, 2012, before the opening of the market.
EDAP will hold a conference call on Wednesday, Novemb...
|
|
EDAP Highlights HIFU Expertise at Third International Symposium on Focused Ultrasound in Washington, D.C.
Oct 25, 2012
|
10.4 KB |
|
| |
LYON, France, Oct. 25, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced its recent participation at the Third International Symposium on Focused Ultrasound, which took place in Washington D.C. from October 14-17, 2012.
At the symposium, urologists with long-term Ablatherm-HIFU (High ...
|
|
EDAP Appoints Experienced Lithotripsy Expert to Increase U.S. Sales
Oct 9, 2012
|
10.3 KB |
|
| |
LYON, France, Oct. 9, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today the appointment of Bill Brown as U.S. based Senior Sales Manager. Mr. Brown joins EDAP's U.S. team to enhance the market penetration of the Company's Sonolith i-move extracorporeal lithotripsy (ESWL) system, expand ...
|
|
EDAP Reports Second Quarter 2012 Revenues Up 61%
Aug 30, 2012
|
30.5 KB |
|
| |
Second Quarter 2012 Highlights
Revenues increased 61% year-over-year to EUR 6.1 million (USD 7.8 million)
Strong lithotripsy sales with fourteen devices sold globally
Strengthened third quarter device backlog to sixteen lithotripsy devices at the end of August 2012
Completed U.S. FDA HIFU trial two year f...
|
|
EDAP Retains Greenleaf Health as Strategic Advisor on U.S. FDA Submission
Aug 29, 2012
|
11.3 KB |
|
| |
LYON, France, Aug. 29, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the retention of Greenleaf Health LLC, a full service regulatory consulting firm. Greenleaf Health will provide the Company with high-level strategic guidance regarding the final stages of its Ablatherm-HIFU (High ...
|
|
|
